ACTRN12624000115538
Not yet recruiting
Phase 1
A study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ELVN-001 Following Single Doses of Capsule and Tablet Administration in the Presence or Absence of High-Fat Food and/or Proton Pump Inhibitors (PPI) in Normal Healthy Participants- Part A
Overview
- Phase
- Phase 1
- Status
- Not yet recruiting
- Sponsor
- Enliven Therapeutics, Inc.
- Enrollment
- 15
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Randomised controlled trial
- Primary Purpose
- Treatment
Eligibility Criteria
- Ages
- 18 Years to 60 Years (—)
- Sex
- All
Inclusion Criteria
- •1\. Participants more than equal to 18 and less than equal to 60 years of age at time of informed consent.
- •2\. Normal healthy male and female participants with no clinically significant medical history, and no clinically significant abnormalities on physical examination at Screening and/or before the first administration of IP at the discretion of the PI or designee.
- •3\. Able to provide written informed consent to participate in this study.
- •4\. Healthy and free from clinically significant illness or disease with clinical laboratory values at Screening and Day \-1 (including haematology, biochemistry, coagulation, and urinalysis) within normal range as specified by the testing laboratory, unless deemed not clinically significant by the PI or designee.
- •5\. Has a body mass index (BMI) more than equal to 18\.5 and less than equal to 32 kg/metre square, inclusive, and weigh between more than equal to 50 kg and less than equal to 100 kg, inclusive, at Screening.
- •6\. Able to understand the nature of the study and any risks associated with participation and willing to cooperate and comply with protocol restrictions and requirements.
- •7\. Agrees to the meals, dietary and lifestyle requirements as outlined in the protocol.
- •8\. Estimated glomerular filtration rate (eGFR): more than equal to 80 mL/min/1\.73 metre square for all participants using the Chronic Kidney Disease Epidemiology Collaboration (CKD\-EPI) creatinine equation.
- •9\. Systolic blood pressure more than equal to 90 and less than equal to 140 mmHg and diastolic blood pressure more than equal to 40 and less than equal to 90 mmHg.
- •10\. Resting heart rate more than equal to 45 and less than equal to 100 beats per minute (bpm).
Exclusion Criteria
- •1\. Previous participating in a trial with ELVN\-001 or participating in another clinical trial within 30 days prior to first dose of the IP.
- •2\. Received any prescribed systemic or topical medications, or live vaccination within 30 days (or less than 5 half\-lives, whichever is longer) or any inactivated vaccination within 72 hours prior to first dose of the IP.
- •3\. Potential participant has used any other IP or investigational medical device within 30 days prior to Screening.
- •4\. Family history (biological relatives \[ie, parents, siblings]) of long or short QT syndrome or Torsades de Pointes.
- •5\. Abnormal ECG findings at Screening or Day \-1 (eg, repeated demonstration of a QTc interval \> 450 msec \[male] or \> 470 msec \[female] corrected by Fridericia’s formula \[QTcF] or Bazett’s formula \[QTcB]) that are considered by the PI or designee to be clinically significant.
- •6\. Presence or history of drug and or alcohol abuse including a positive result on the urine drug screen or alcohol breath test at Screening or Day \-1\.
- •7\. Excessive intake of caffeine\-containing drinks or food as judged by the PI. Excessive intake is defined as more than 400 mg of caffeine per day (equivalent to 4 or 5 cups of brewed coffee).
- •8\. Use of tobacco or nicotine\-containing products (including e\-cigarettes) within 3 months prior to first dose of IP and during the course of the study.
- •9\. Test positive for hepatitis B surface antigen, hepatitis B core antibody, hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) 1 and HIV 2 antibodies. If a participant tests positive for HCV antibodies, they may still be allowed into the trial if HCV ribonucleic acid (RNA) is undetectable in a Follow\-up assessment.
- •10\. Plasma donation within 30 days of Screening or any blood/loss or donation more than 500 mL during the 90 days prior to Screening.
Investigators
Similar Trials
Not yet recruiting
Phase 1
A study to evaluate safety, tolerability and pharmacokinetics of ELVN-001 in Normal Healthy Participants- Part BChronic Myeloid Leukaemia (CML)Parkinson's Disease (PD)Cancer - Leukaemia - Chronic leukaemiaNeurological - Parkinson's diseaseACTRN12624000116527Enliven Therapeutics, Inc.15
Active, not recruiting
Phase 1
A Study to Test if TV-46000 is Safe for Maintenance Treatment of SchizophreniaMaintenance treatment of schizophrenia in patients currently treated with oral antipsychoticsMedDRA version: 20.0Level: PTClassification code 10039626Term: SchizophreniaSystem Organ Class: 10037175 - Psychiatric disordersTherapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]EUCTR2019-000063-24-FRTeva Branded Pharmaceutical Products R&D, Inc.300
Completed
Not Applicable
A Study to Evaluate the Safety, Tolerability, and Effects on NSAID-Induced Small Bowel Pathology of K-196 in Healthy Volunteers.Inflammatory bowel disease (IBD)10017969NL-OMON51579Kallyope, Inc.70
Active, not recruiting
Phase 1
A Study to Test if TV-46000 is Safe for Maintenance Treatment of SchizophreniaEUCTR2019-000063-24-BGTeva Branded Pharmaceutical Products R&D, Inc.340
Completed
Not Applicable
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Donepezil with Glycopyrrolate or Trospium in Elderly VolunteersAlzheimer's diseasedementia1004225810012272NL-OMON45462Axovant Sciences Ltd.75